LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Efficacy of topical hemostatic agents in malignancy-related GI bleeding: a systematic review and meta-analysis.

    Karna, Rahul / Deliwala, Smit / Ramgopal, Balasubramanian / Mohan, Babu P / Kassab, Lena / Becq, Aymeric / Dhawan, Manish / Adler, Douglas G

    Gastrointestinal endoscopy

    2022  Volume 97, Issue 2, Page(s) 202–208.e8

    Abstract: Background and aims: Despite advances in endoscopic therapies, malignancy-related GI bleeding remains difficult to manage with high rates of treatment failure and rebleeding. Topical hemostatic agents (THAs) are easier to apply to the wide bleeding ... ...

    Abstract Background and aims: Despite advances in endoscopic therapies, malignancy-related GI bleeding remains difficult to manage with high rates of treatment failure and rebleeding. Topical hemostatic agents (THAs) are easier to apply to the wide bleeding surface of tumors. We conducted this systematic review and meta-analysis to evaluate the efficacy of THAs in malignancy-related GI bleeding.
    Methods: We conducted a comprehensive search of multiple electronic databases to identify studies reporting on the use of THAs in malignancy-related GI bleeding. The primary outcome was the achievement of hemostasis; secondary outcomes were early rebleeding (≤3 days), delayed rebleeding (>3 days), aggregate rebleeding, all-cause mortality, and GI bleeding-related mortality. A meta-analysis of proportions was done for all outcomes.
    Results: Out of 355 citations, 16 studies with 530 patients were included. Primary hemostasis was achieved in 94.1% (95% confidence interval [CI], 91.5-96.0). Early rebleeding was seen in 13.9% (95% CI, 9.7-19.4) and delayed rebleeding in 11.4% (95% CI, 5.8-21.1). Aggregate rebleeding was seen in 24.2% (95% CI, 18.5-31.0). All-cause mortality was 33.1% (95% CI, 23.7-44.0), whereas GI bleeding-related mortality occurred in 5.9% (95% CI, 2.2%-14.8).
    Conclusions: THAs are highly effective for achieving primary hemostasis in malignancy-related GI bleeding. It should be considered as an alternative to traditional endotherapy methods in malignancy-related GI bleeding. Future studies should be designed to evaluate its efficacy and safety as a primary method of hemostasis as compared with traditional endotherapy measures.
    MeSH term(s) Humans ; Hemostasis, Endoscopic/methods ; Neoplasm Recurrence, Local/complications ; Gastrointestinal Hemorrhage/drug therapy ; Gastrointestinal Hemorrhage/etiology ; Hemostatics/therapeutic use ; Recurrence
    Chemical Substances Hemostatics
    Language English
    Publishing date 2022-08-06
    Publishing country United States
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 391583-9
    ISSN 1097-6779 ; 0016-5107
    ISSN (online) 1097-6779
    ISSN 0016-5107
    DOI 10.1016/j.gie.2022.07.033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Gastrointestinal treatment-related adverse events of combined immune checkpoint inhibitors: a meta-analysis.

    Karna, Rahul / S Deliwala, Smit / Ramgopal, Balasubramanian / Asawa, Palash / Mishra, Rahul / P Mohan, Babu / Jayakrishnan, Thejus / Grover, Dheera / Kalra, Tanisha / Bhalla, Jaideep / Saraswati, Ushasi / K Gangwani, Manesh / Dhawan, Manish / G Adler, Douglas

    Immunotherapy

    2023  Volume 15, Issue 10, Page(s) 773–786

    Abstract: Introduction: ...

    Abstract Introduction:
    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/adverse effects ; Neoplasms/drug therapy ; Diarrhea ; Colon
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-05-16
    Publishing country England
    Document type Meta-Analysis ; Journal Article
    ZDB-ID 2495964-9
    ISSN 1750-7448 ; 1750-743X
    ISSN (online) 1750-7448
    ISSN 1750-743X
    DOI 10.2217/imt-2023-0001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Atrial fibrillation cryoablation is an effective day case treatment: the UK PolarX vs. Arctic Front Advance experience.

    Honarbakhsh, Shohreh / Martin, Claire A / Mesquita, Joao / Herlekar, Rahul / Till, Richard / Srinivasan, Neil T / Duncan, Edward / Leong, Fong / Dulai, Rajdip / Veasey, Rick / Panikker, Sandeep / Paisey, John / Ramgopal, Balasubramanian / Das, Moloy / Ahmed, Wissam / Sahu, Jonathan / Earley, Mark J / Finlay, Malcolm C / Schilling, Richard J /
    Hunter, Ross J

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

    2023  Volume 25, Issue 11

    Abstract: Aims: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation (AF). There are limited data on the PolarX Cryoballoon. The study aimed to establish the safety, efficacy, and feasibility of same day discharge for ... ...

    Abstract Aims: Pulmonary vein isolation (PVI) is the cornerstone of catheter ablation for atrial fibrillation (AF). There are limited data on the PolarX Cryoballoon. The study aimed to establish the safety, efficacy, and feasibility of same day discharge for Cryoballoon PVI.
    Methods and results: Multi-centre study across 12 centres. Procedural metrics, safety profile, and procedural efficacy of the PolarX Cryoballoon with the Arctic Front Advance (AFA) Cryoballoon were compared in a cohort large enough to provide definitive comparative data. A total of 1688 patients underwent PVI with cryoablation (50% PolarX and 50% AFA). Successful PVI was achieved with 1677 (99.3%) patients with 97.2% (n = 1641) performed as day case procedures with a complication rate of <1%. Safety, procedural metrics, and efficacy of the PolarX Cryoballoon were comparable with the AFA cohort. The PolarX Cryoballoon demonstrated a nadir temperature of -54.6 ± 7.6°C, temperature at 30 s of -38.6 ± 7.2°C, time to -40°C of 34.1 ± 13.7 s, and time to isolation of 49.8 ± 33.2 s. Independent predictors for achieving PVI included time to reach -40°C [odds ratio (OR) 1.34; P < 0.001] and nadir temperature (OR 1.24; P < 0.001) with an optimal cut-off of ≤34 s [area under the curve (AUC) 0.73; P < 0.001] and nadir temperature of ≤-54.0°C (AUC 0.71; P < 0.001), respectively.
    Conclusions: This large-scale UK multi-centre study has shown that Cryoballoon PVI is a safe, effective day case procedure. PVI using the PolarX Cryoballoon was similarly safe and effective as the AFA Cryoballoon. The cryoablation metrics achieved with the PolarX Cryoballoon were different to that reported with the AFA Cryoballoon. Modified cryoablation targets are required when utilizing the PolarX Cryoballoon.
    MeSH term(s) Humans ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/surgery ; Cryosurgery/adverse effects ; Cryosurgery/methods ; Treatment Outcome ; Time Factors ; Pulmonary Veins/surgery ; Catheter Ablation/methods ; United Kingdom ; Recurrence
    Language English
    Publishing date 2023-09-22
    Publishing country England
    Document type Multicenter Study ; Journal Article
    ZDB-ID 1449879-0
    ISSN 1532-2092 ; 1099-5129
    ISSN (online) 1532-2092
    ISSN 1099-5129
    DOI 10.1093/europace/euad286
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top